"Again, revealing my scientific ignorance, is there any evidence that apabetalone might achieve reduced 3 pt MACE at higher dosages using a phased/intermittent dosage plan???"

ASSERT was the only Phase 2 trial to test doses above 200 mg/day. ASSERT tested 100, 200 and 300 mg/day. These were all daily dosing; no intermittent dosing. You can look back at published ASSERT trial for dose response related observations. But probably not enough patients treated at 300 mg to conclude much at all related to MACE. Plus, ASSERT was only 12 week dosing.

BDAZ